Drug development research agreement leverages simulation platform

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/rawpixel)
(Image: Getty/rawpixel)

Related tags: Research, Simulation, Drug development, Drug development process, Translational medicine, Biology, Antibody drug conjugates

Drug development advisory firm Rosa & Co. enters research agreement with Chugai pharmaceutical to provide access to PhysioPD research services for translational biology.

Chugai, a member of the Roche group, will receive access to Rosa’s research and development services, PhysioPD, a quantitative systems pharmacology approach to translate biology into an interactive simulation platform. The approach translates biology into an interactive simulation platform to represent physiology, disease, and intervention effects.

Per the collaboration, Chugai will use this service across multiple therapeutic areas on its research and development pipeline to discover actionable program recommendations to reduce risk and address consequential decisions regarding drug development.

Rosa and Chugai have engaged in projects together in the past. “We are extremely pleased to extend our relationship with Chugai. Over the last several years we have been working with them on various projects and this agreement validates the value PhysioPD Research brings,”​ Ron Beaver, founder and CEO of Rosa, said in a statement.

Chugai launched the first antibody-drug created in Japan in the 1990s and is currently focused on its proprietary antibody engineering technologies for antibody drug development.

Kimio Terao, department manager of clinical pharmacology and translational research at Chugai, said in a statement, “Chugai strives to develop hand in hand with society through the creation of innovative drugs and services. I am convinced that Rosa's novel platform will provide a powerful tool to transform our research into real innovation.”

Related news

Related products

Q2 Solutions: Corporate Brochure

Q2 Solutions: Corporate Brochure

Q2 Solutions | 17-Apr-2020 | Product Brochure

We are an innovative, progressive and responsive partner with the global experience, medical expertise and focus on quality that is integral to drug, medical...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more